Why the study?
Does levofloxacin reduce the risk of QT prolongation and torsades de pointes compared to other fluoroquinolones in patients requiring antibiotic therapy?
Does levofloxacin reduce the risk of QT prolongation and torsades de pointes compared to other fluoroquinolones in patients requiring antibiotic therapy?
No takes yet. Share an insight, caveat, or question.
Preclinical and post-marketing data suggest that QT prolongation and torsades de pointes are not a uniform fluoroquinolone class effect, with levofloxacin demonstrating a very low risk.
James B. Kahn (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: